Biopharma: EASL 2026 Planner Covering Oral Presentations, Posters, and Publications

Research evidence excerpt

Biopharma: EASL 2026 Planner Covering Oral Presentations, Posters, and Publications

duce sustained HSD17B13 suppression and liver biochemical

Poster Arrowhead Pharma MASLD: Therapy MASH GSK4532990 HSD17B13 FRI-169 REG26-214

improvement in patients with metabolic dysfunction-associated steatohepatitis

Alcohol-related liver disease and MetALD - Safety and pharmacokinetic results from a Phase 2 safety lead-in in participants with hepatic impairment support

Oral Arrowhead Pharma MASH GSK4532990 HSD17B13 OS-031 REG26-230

Clinical continued development of GSK4532990 in alcohol-related liver disease

A PNPLA3 antisense oligonucleotide, AZD2693, for the treatment of MASH in I148M homozygous participants:

Oral AstraZeneca MASLD: Therapy MASH AZD2693 PNPLA3 GS-003 REG26-1411

results from the phase 2b FORTUNA study

Portal Hypertension (cirrhosis and non- Risk reduction in clinically significant portal hypertension with Belapectin in advanced MASH cirrhosis: results

Poster Galectin Tx MASH-Cirrhosis Belapectin Galectin 3 TOP-486 REG26-612

cirrhosis) from the NAVIGATE trial

Once-monthly efimosfermin alfa in participants with metabolic dysfunction associated steatohepatitis with F2/F3

Poster GSK Late-breaking MASH F2-F3 Efimosfermin alfa FGF21 LBP-025 LB26-5224

fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial

HSK31679, a thyroid hormone receptor beta agonist, improves histological outcomes in Asian patients with MASH

Poster Haisco Pharma Late-breaking MASH HSK31679 THR-β LBP-041 LB26-5013

and F2–F3- fibrosis: a 52-week phase 2b randomized, double blind, placebo-controlled trial

Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are